A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations is a phase 1/2, interventional study registered as NCT06412198 by M.D. Anderson Cancer Center, with a registry enrolment figure of 31 participants, started 2024-08-28 and due to reach its primary completion in 2029-03-01. Interventions recorded: Cetuximab; Cemiplimab; Adagrasib. Conditions listed: Metastatic Colorectal Cancer; KRAS G12C Mutations. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of therapy". Sites: United States. No results are recorded here; the registry entry is the source.